Latest news with #Mazur
Yahoo
14-05-2025
- Business
- Yahoo
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal quarter ended March 31, 2025. "As we continue to focus on the planned launch of our first FDA-approved product, LYMPHIR, through Citius Oncology, we are actively engaged in securing the necessary financing to advance our launch strategy in the coming months, as well as exploring strategic partners for Citius Oncology," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals and Citius Oncology. "We are also in the process of preparing a submission to the FDA that reflects the valuable feedback we received from the agency concerning clinical efficacy, safety data, and in-vitro data. This submission is a key step toward supporting a future New Drug Application (NDA) for our Mino-Lok program. As a reminder, our Phase 3 Trial, which was completed last year, met its primary endpoints," added Mazur. "During the quarter, we took deliberate steps to strengthen our financial position, including completing a registered direct offering and leveraging our existing at-the-market sales agreement to ensure capital flexibility. We also amended our license agreement with Eisai to align our payment obligations with our commercialization timeline. With these efforts underway, we believe we are positioned to deliver long-term value to patients and shareholders alike," concluded Mazur. FISCAL SECOND QUARTER 2025 FINANCIAL RESULTS: Liquidity During the six months ended March 31, 2025, the Company received net proceeds of $6 million from the issuance of equity. On April 2, 2025, the Company closed on a registered direct offering to an institutional investor of our common stock and pre-funded warrants to purchase common stock. The net proceeds to the Company from the offering were approximately $1.735 million, after deducting placement agent fees and other offering expenses payable by the Company. As of March 31, 2025, the Company had $26,410 in cash and cash equivalents and 8,760,649 common shares outstanding excluding the April 2, 2025 financing. Citius Pharma will need to secure additional capital to support operations beyond May 2025. Until Citius Oncology raises adequate capital through equity financings from outside investors and/or generates revenue from the future sales of LYMPHIR, Citius Pharma plans to continue to fund Citius Oncology. Citius Oncology has also retained Jefferies LLC as its exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value. Research and Development (R&D) Expenses R&D expenses were $3.8 million for the quarter ended March 31, 2025, as compared to $3.6 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, R&D expenses were $5.9 million, as compared to $6.3 million during the six months ended March 31, 2024. R&D expenses primarily reflect LYMPHIR-related costs. Research and development costs for LYMPHIR were $5.3 during the six months ended March 31, 2025, as compared to $3.2 million for the six months ended March 31, 2024. The $2.1 million increase in expenses was primarily due to costs associated with the expense of a drug substance batch needed for the pre license inspection of the manufacturer. R&D expenses related to Mino-Lok decreased due to completion of the Phase 3 trial. There were no Halo Lido R&D expenses during the quarter, and $11 thousand was recorded for the six months ended March 31, 2025. We expect that research and development expenses will continue to decrease in fiscal 2025 as we continue to focus on the commercialization of LYMPHIR and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $4.8 million for the quarter ended March 31, 2025, as compared to $4.3 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, G&A expenses were $10.2 million, as compared to $7.9 million for the six months ended March 31, 2024. The increase was primarily due to higher costs for pre-launch commercial activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting, and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the quarter ended March 31, 2025, stock-based compensation expense was $2.7 million, as compared to $3.1 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, stock-based compensation expense was $5.2 million, as compared to $6.1 million for the six months ended March 31, 2024. Stock-based compensation expense is primarily related to the Citius Oncology stock plans. The decrease compared to the prior year is due to lower costs associated with the Citius Pharma stock plans. Net loss Net loss was $11.5 million, or ($1.27) per share, for the quarter ended March 31, 2025, as compared to a net loss of $8.5 million, or ($1.34) per share, for the quarter ended March 31, 2024, as adjusted for the reverse stock split. The increase in net loss was due to a $2.6 million decrease in other income, offset by the increase in general and administrative expenses and research and development expenses. For the six months ended March 31, 2025, we incurred a net loss of $21.8 million, as compared to a net loss of $17.8 million for the six months ended March 31, 2024. The $4.0 million increase in the net loss was primarily due to the increase of $2.2 million in general and administrative expenses and the decrease in other income of $2.9 million, partially offset by lower research and development expense and lower stock-based compensation expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR™, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. Citius Pharma owns 92% of Citius Oncology. For more information, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond May 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services, through our majority-owned subsidiary and any of our other product candidates that may be approved by the FDA; our ability to maintain compliance with Nasdaq's continued listing standards; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Pharma's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allenir@ x113 Media Contact: STiR-communicationsGreg SalsburgGreg@ -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)March 31, September 30, 2025 2024 ASSETSCurrent Assets:Cash and cash equivalents$ 26,410 $ 3,251,880 Inventory 15,339,2538,268,766 Prepaid expenses 3,008,7912,700,000 Total Current Assets 18,374,45414,220,646 Operating lease right-of-use asset, net 922,099246,247 Deposits 38,06238,062 In-process research and development 92,800,00092,800,000 Goodwill 9,346,7969,346,796 Total Other Assets 102,184,858102,184,858 Total Assets$ 121,481,411 $ 116,651,751 LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$ 9,368,234 $ 4,927,211 License payable 28,400,00028,400,000 Accrued expenses 8,779,24417,027 Accrued compensation 3,184,0662,229,018 Operating lease liability 145,098241,547 Total Current Liabilities 49,876,64235,814,803 Deferred tax liability 7,242,2806,713,800 Operating lease liability - noncurrent 786,69721,318 Total Liabilities 57,905,61942,549,921 Commitments and ContingenciesStockholders' Equity:Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding -- Common stock - $0.001 par value; 16,000,000 shares authorized; 8,760,649 and 7,247,243 shares issued and outstanding at March 31, 2025 and September 30, 2024, respectively 8,7617,247 Additional paid-in capital 282,705,620271,440,421 Accumulated deficit (222,054,969)(201,370,218) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 60,659,41270,077,450 Non-controlling interest 2,916,3804,024,380 Total Equity 63,575,79274,101,830 Total Liabilities and Equity$ 121,481,411 $ 116,651,751Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited)Three Months Ended Six Months Ended March 31, March 31, March 31, March 31, 2025 2024 2025 2024 Revenues$ — $ — $ — $ — Operating ExpensesResearch and development 3,766,5253,605,8985,893,5636,227,808 General and administrative 4,792,1224,285,91110,179,8747,946,639 Stock-based compensation – general and administrative 2,702,0313,078,3925,226,8556,136,577 Total Operating Expenses 11,260,67810,970,20121,300,29220,311,024 Operating Loss (11,260,678)(10,970,201)(21,300,292)(20,311,024) Other IncomeInterest income 13,413182,20536,021435,843 Gain on sale of New Jersey net operating losses —2,387,842—2,387,842 Total Other Income 13,4132,570,04736,0212,823,685 Loss before Income Taxes (11,247,265)(8,400,154)(21,264,271)(17,487,339) Income tax expense 264,240144,000528,480288,000 Net Loss$ (11,511,505) $ (8,544,154) $ (21,792,751) $ (17,775,339) Net loss attributable to non-controlling interest 595,000—1,108,000— Net loss applicable to common stockholders (10,916,505)(8,544,154)(20,684,751)(17,775,339) Net Loss Per Share - Basic and Diluted$ (1.27) $ (1.34) $ (2.58) $ (2.79) Weighted Average Common Shares OutstandingBasic and diluted 8,581,2076,362,8908,029,8346,360,551Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited)2025 2024 Cash Flows From Operating Activities:Net loss$ (21,792,751) $ (17,775,339) Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense 5,226,8556,136,577 Issuance of common stock for services -174,225 Amortization of operating lease right-of-use assets 110,845101,921 Depreciation -1,157 Deferred income tax expense 528,480288,000 Changes in operating assets and liabilities:Inventory (7,070,487)- Prepaid expenses (308,791)(1,124,618) Accounts payable 4,441,023(257,827) Accrued expenses 8,762,217(325,096) Accrued compensation 955,048(1,033,907) Operating lease liability (117,767)(106,414) Net Cash Used In Operating Activities (9,265,328)(13,921,321) Cash Flows From Financing Activities:Net proceeds from common stock offerings 6,039,858- Net Cash Provided By Financing Activities 6,039,858- Net Change in Cash and Cash Equivalents (3,225,470)(13,921,321) Cash and Cash Equivalents - Beginning of Period 3,251,88026,480,928 Cash and Cash Equivalents - End of Period$ 26,410 $ 12,559,607 Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:Operating lease right-of-use asset and liability recorded$ 786,697 $ — View original content to download multimedia: SOURCE Citius Pharmaceuticals, Inc. Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a development-stage company to a commercial-stage organization. Following FDA approval of LYMPHIR, we intensified our focus on disciplined capital deployment and operational execution to support the success of our planned U.S. launch," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "This quarter's progress underscores our commitment to creating long-term value by ensuring LYMPHIR reaches patients with cutaneous T-cell lymphoma. Discussions with prospective commercial and strategic partners are underway as we concurrently pursue opportunities to secure additional capital to enhance our financial flexibility. These efforts are critical as we lay the foundation for sustained commercial success. With disciplined execution and a focused strategic vision, we believe Citius Oncology is poised to deliver meaningful near-term impact and durable shareholder value," concluded Mazur. FISCAL SECOND QUARTER 2025 FINANCIAL RESULTS: Liquidity Citius Oncology is a subsidiary of Citius Pharma. Citius Pharma plans to continue to fund Citius Oncology until Citius Oncology raises adequate capital through equity financings from outside investors and/or generates revenue from the future sales of LYMPHIR. Citius Oncology has also retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value. As of March 31, 2025, the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding. Citius Oncology will need to secure additional capital to support operations beyond May 2025. Research and Development (R&D) Expenses R&D expenses were $3.1 million for the quarter ended March 31, 2025, as compared to $1.3 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, R&D expenses were $4.4 million, as compared to $2.5 million for the six months ended March 31, 2024. The increase is primarily related to costs associated with the expense of a drug substance batch needed for the pre-license inspection of the manufacturer. General and Administrative (G&A) Expenses G&A expenses were $2.2 million for the quarter ended March 31, 2025, as compared to $1.4 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, G&A expenses were $5.5 million, as compared to $2.9 million for the six months ended March 31, 2024. The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the quarter ended March 31, 2025, stock-based compensation expense was $2.1 million, as compared to $2.0 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, stock-based compensation expense was $3.9 million, as compared to $3.9 million for the six months ended March 31, 2024. The increase was primarily due to new options granted in December 2024. Net loss Net loss was $7.7 million, or ($0.11) per share, for the quarter ended March 31, 2025, as compared to a net loss of $4.8 million, or ($0.07) per share, for the quarter ended March 31, 2024. Net loss for the six months ended March 31, 2025 was $14.4 million, as compared to a net loss of $9.6 million for the six months ended March 31, 2024. The increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond May 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services, and any of our other product candidates that may be approved by the FDA; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to regain compliance with Nasdaq's continued listing standards; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Oncology's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@ 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@ -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)March 31, 2025 September 30, 2024Current Assets: Cash and cash equivalents$ 112 $ 112Inventory 15,339,2538,268,766Prepaid expenses 2,700,0002,700,000Total Current Assets 18,039,36510,968,878 Other Assets: In-process research and development 73,400,00073,400,000Total Other Assets 73,400,00073,400,000 Total Assets$ 91,439,365 $ 84,368,878LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable$ 7,676,310 $ 3,711,622License payable 28,400,00028,400,000Accrued expenses 8,722,168—Due to related party 4,941,664588,806Total Current Liabilities 49,740,14232,700,428 Deferred tax liability 2,256,4801,728,000Note payable to related party 3,800,1113,800,111Total Liabilities 55,796,73338,228,539Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding ——Common stock - $0.0001 par value; 100,000,000; 71,552,402 shares issued and outstanding at March 31, 2025 and September 30, 2024 7,1557,155Additional paid-in capital 89,308,82185,411,771Accumulated deficit (53,673,344)(39,278,587)Total Stockholders' Equity 35,642,63246,140,339Total Liabilities and Stockholders' Equity$ 91,439,365 $ 84,368,878 CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited)Three Months Ended Six Months EndedMarch 31, March 31, March 31, March 31,2025 2024 2025 2024Revenues$ — $ — $ — $ — Operating Expenses Research and development 3,139,4131,348,9664,403,9212,497,461General and administrative 2,243,3271,385,5805,565,3062,903,488Stock-based compensation – general and administrative 2,088,5721,957,0003,897,0503,874,000Total Operating Expenses 7,471,3124,691,54613,866,2779,274,949 Loss before Income Taxes (7,471,312)(4,691,546)(13,866,277)(9,274,949)Income tax expense 264,240144,000528,480288,000 Net Loss$ (7,735,552) $ (4,835,546) $ (14,394,757) $ (9,562,949) Net Loss Per Share - Basic and Diluted$ (0.11) $ (0.07) $ (0.20) $ (0.14) Weighted Average Common Shares Outstanding Basic and diluted 71,552,40267,500,00071,552,40267,500,000 CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited)2025 2024Cash Flows From Operating Activities: Net loss$ (14,394,757) $ (9,562,949)Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 3,897,0503,874,000 Deferred income tax expense 528,480288,000Changes in operating assets and liabilities: Inventory (7,070,487) Prepaid expenses (1,171,920) Accounts payable 3,964,688(785,132) Accrued expenses 8,722,168(259,071) Due to related party 4,352,8587,617,072Net Cash Provided By Operating Activities -- Net Change in Cash and Cash Equivalents --Cash and Cash Equivalents – Beginning of Period 112-Cash and Cash Equivalents – End of Period$ 112 $ - View original content to download multimedia: SOURCE Citius Oncology, Inc. Sign in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City. Conference Details: Presentation: 3:10 pm ET on Thursday, June 5, 2025* Location: New York City Webcast: A live and archived webcast of the presentation will be available here. A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Citius website In addition to the formal presentation, Mr. Mazur will participate in one-on-one meetings with institutional investors throughout the conference. Investors interested in scheduling a meeting should contact their Jefferies representative. *Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information. About Citius Oncology, Inc. Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit Investor Contact: Ilanit Allenir@ x113 Media Contact: STiR-communicationsGreg SalsburgGreg@ View original content to download multimedia: SOURCE Citius Pharmaceuticals, Inc. Sign in to access your portfolio
Yahoo
26-03-2025
- Business
- Yahoo
AM Best to Sponsor and Join Panel Discussion at Annual CIRCA ReConnect Conference
OLDWICK, N.J., March 26, 2025--(BUSINESS WIRE)--AM Best Managing Director Brad Mazur will participate in a panel discussion at the upcoming Cayman International Reinsurance Companies Association's (CIRCA) ReConnect Conference. The event takes place April 10–11, 2025, at the Ritz Carlton, Grand Cayman. Brad Mazur will be participating in a panel discussion, titled, "Discover Cayman: Your Guide to Setting up a Reinsurer" on Thursday, April 10, 2025, from 10:00 a.m.-10:45 a.m. The session will be moderated by Jacob MacAdam, partner, Appleby; other panelists include Lloyd Balshaw, director, Deloitte; Ahwaz Chagani, president and CEO, Oceanview Secure Reinsurance Ltd.; and Britni Strong, director, Strategic Risk Solutions. Mazur is the managing director of business development at AM Best. He served in various senior level roles in the financial services industry before joining AM Best in 2016. CIRCA is the industry group for commercial reinsurers located in the Cayman Islands, dedicated to fostering the industry through peer interaction, advocacy and education on topics impacting the regulatory and business environment. To view the official agenda and learn more about the CIRCA ReConnect Conference, please visit the event overview. To arrange a meeting with Mazur, please contact him at +1 908 882 2099 or AM Best is also a delegate bag sponsor at the event. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Christopher SharkeyAssociate Director, Public Relations+1 908 882 Al SlavinSenior Public Relations Specialist+1 908 882
Yahoo
20-03-2025
- Health
- Yahoo
House panel endorses bills to ban medical procedures for transgender minors
Mar. 19—A key House committee endorsed two bills along party lines to prevent minors from getting hormone treatments or breast surgeries tied to their attempts to transition from one gender to another. State Rep. Lisa Mazur, R-Goffstown, said a growing number of health care providers are declining to provide these procedures because some minors later regret altering their bodies. "I know this is an emotional subject. The big question to ask is do children change their minds? If so, please pass this bill because it gives them the time they need to truly understand the long-term impacts of these medical decisions," Mazur said. State Rep. Jessica Lamontagne, D-Dover, chastised Republicans for "hypocrisy," supporting the right of parents to make decisions for their children except when it comes to treatment for transgender minors. "Most people have no regret with this treatment and feel it has changed their lives," Lamontagne said. The House Health, Human Services and Elderly Affairs Committee voted by identical 10-8 margins in favor of these bills banning puberty blockers and hormone treatments (HB 377) and breast surgery for minors that is elective (HB 712). All Republicans on the committee voted for them, all House Democrats opposed them. The ban on puberty blockers would make providing that treatment a Class B felony that could carry up to a 3 1/2 —to 7-year term in state prison. Mazur convinced the committee to amend her bill to allow minors who are getting these treatments to wean off of them over up to a six-month period. Medical providers who gave minors breast surgery services under the second bill could be subject to professional discipline. The bill would permit minors to receive breast surgery to "treat malignancy, injury, infection, or malformation." State banned anti-gay conversion therapy in 2018 Rep. Gary Woods, D-Bow, a retired surgeon, said lawmakers should not interfere in the practice of medicine. "The patient, doctor and parent are involved in medical decision making," Woods said. "What we are asking is for the Legislature to not intervene in that doctor and patient relationship." Mazur said minors are too young to have these procedures. "Children will never ever be able to come back from these life-altering surgeries that remove completely healthy body parts," Mazur said. In 2024, the Republican-led Legislature passed and former Gov. Chris Sununu signed legislation that outlawed minors having surgeries that altered their sex organs. State Rep. Tim Hartnett, D-Manchester, said the legislation goes too far. "This bill isn't banning hormone treatment for everybody. It is banning it for one narrow class of people and that's discriminatory," Hartnett added. Rep. Erica Layon, R-Derry, said many health care providers are reluctant to counsel minors against having these procedures. That's because the Legislature in 2018 outlawed conversion therapy which is the practice of a clinician trying to encourage patients to be heterosexual, she said. What's Next: The full House of Representatives will vote on both bills early next month Prospects: Pretty decent. Conservative Republicans in the House and Senate have supported similar bills in recent years. klandrigan@
